Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | F2 | P00734 | 1/20 | 0.52 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.48 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.47 |
| ▸ | CCR5 | P51681 | 1/20 | 0.46 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.45 |
| ▸ | PTP4A3 | O75365 | 1/20 | 0.45 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.45 |
| ▸ | MAOB | P27338 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24244911 | 0.92 | GSTP1 (0.54) | RAB9ASMN1; SMN2PTPN1MAOBMAPT | |
| SCHEMBL17488404 | 0.91 | RAB9A (0.51) | RAB9ASMN1; SMN2F2MRGPRX4PTPN1 | |
| SCHEMBL19398436 | 0.88 | F2 (0.49) | RAB9ASMN1; SMN2F2MRGPRX4KDM4E | |
| SCHEMBL1756349 | 0.87 | ABCC4 (0.58) | RAB9ASMN1; SMN2MRGPRX4PTPN1SMPD1 | |
| SCHEMBL17293801 | 0.84 | PTPN1 (0.55) | RAB9ASMN1; SMN2F2MRGPRX4PTPN1 | |
| SCHEMBL5276838 | 0.84 | RAB9A (0.51) | RAB9ASMN1; SMN2F2PTPN1KDM4E | |
| SCHEMBL8440333 | 0.84 | SMN1; SMN2 (0.51) | RAB9ASMN1; SMN2F2PTPN1CCR5 | |
| SCHEMBL1756387 | 0.83 | MRGPRX4 (0.73) | RAB9ASMN1; SMN2MRGPRX4HPGDMAPT | |
| SCHEMBL7898169 | 0.82 | RAB9A (0.59) | RAB9ASMN1; SMN2PTPN1CCR5MAOB | |
| SCHEMBL30835101 | 0.82 | RAB9A (0.59) | RAB9ASMN1; SMN2PTPN1CCR5MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2590951-B1 | BENZENESULFONAMIDES USEFUL AS SODIUM CHANNEL INHIBITORS | PFIZER LTD (GB) | 2015-01-07 | — | — | EP | disclosed |
| US-8772293-B2 | Chemical compounds | PFIZER LIMITED (GB) | 2014-07-08 | — | — | US | disclosed |
| EP-2590951-A1 | BENZENESULFONAMIDES USEFUL AS SODIUM CHANNEL INHIBITORS | Pfizer Limited (GB) | 2013-05-15 | — | — | EP | disclosed |
| WO-2012004743-A1 | BENZENESULFONAMIDES USEFUL AS SODIUM CHANNEL INHIBITORS | PFIZER LIMITED (GB) | 2012-01-12 | — | — | WO | disclosed |
| US-20120010182-A1 | Chemical Compounds | ICAGEN INC. (US) | 2012-01-12 | — | — | US | disclosed |
| US-7915455-B2 | Transition metal complex ligand and olefin polymerization catalyst containing transition metal complex | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2011-03-29 | — | — | US | disclosed |
| US-7915455-B2 | Transition metal complex ligand and olefin polymerization catalyst containing transition metal complex | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2011-03-29 | — | — | US | disclosed |
| US-20090143620-A1 | Transition metal complex ligand and olefin polymerization catalyst containing transition metal complex | SUMITOMO CHEMICAL COMPANY, LIMITED | 2009-06-04 | — | — | US | disclosed |
| US-7482414-B2 | Transition metal complex ligand and olefin polymerization catalyst containing transition metal complex | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2009-01-27 | — | — | US | disclosed |
| US-20070135600-A1 | Transition metal complex ligand and olefin polymerization catalyst containing transition metal complex | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2007-06-14 | — | — | US | disclosed |
| US-20070135600-A1 | Transition metal complex ligand and olefin polymerization catalyst containing transition metal complex | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2007-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070135600-A1 | Transition metal complex ligand and olefin polymerization catalyst containing transition metal complex | AP1M1, OR10J3, AP2M1 | RAB9A 977/4885SMN1; SMN2 2171/4885F2 38/4885 |
| US-20090143620-A1 | Transition metal complex ligand and olefin polymerization catalyst containing transition metal complex | AP1M1, OR10J3, AP2M1 | RAB9A 977/4885SMN1; SMN2 2171/4885F2 38/4885 |
| US-20120010182-A1 | Chemical Compounds | SCN1A, SCN1B, CACNA1E | RAB9A 247/4885SMN1; SMN2 333/4885F2 3542/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.